Company: HURA
Filing Date: 2025-05-07
Form Type: 8-K
Source: 0000950170-25-065057
Chunk: 8

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-07
Form: 8-K
Item: Item 1.01
Chunk 8
---
ation Agreement also provides that Mr. Yamashita vested as to 65,597 of his previously granted options, all of which will be exercisable through January 19, 2027. As a part of the Separation Agreement, Mr. Yamashita has agreed to a general release and waiver of claims against the Company upon the terms more particularly set forth in the Separation Agreement.

The foregoing description of the Separation Agreement does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Separation Agreement, which is attached as Exhibit 10.1 hereto and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

  Exhibit      Description                                                                                                                                                                                           
      No.                                                                                                                                                                                                            
      2.1      First Amendment to the Agreement and Plan of Merger, dated May 5, 2025, by and among TuHURA, Kineta, the Merger Subs and the Stockholders Representative (incorporated by reference to Exhibit 2....  
     10.1      Separation Agreement, dated May 5, 2025, between TuHURA Biosciences, Inc. and Dennis Yamashita.                                                                                                       
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────